New hope for hard-to-treat myeloma: experimental combo targets relapsed patients

NCT ID NCT07096778

Recruiting now Disease control Sponsor: CellCentric Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This study tests a new drug, inobrodib, combined with two standard medicines (pomalidomide and dexamethasone) in 100 adults whose multiple myeloma has come back or no longer responds to available therapies. The goal is to see how well the combination shrinks tumors and to learn more about its side effects. Participants will know they are receiving the experimental treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA IN RELAPSE MULTIPLE MYELOMA REFRACTORY

Contacts and locations

Locations

American Oncology Partners, PA
RECRUITING

Bethesda, Maryland, 20817, United States
Barts Health NHS Trust
RECRUITING

London, EC1A 7BE, United Kingdom
Cleveland Clinic
RECRUITING

Cleveland, Ohio, 44195, United States
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Fred Hutchinson Cancer Center
RECRUITING

Seattle, Washington, 98109, United States
Froedtert Hospital & the Medical College of Wisconsin
RECRUITING

Milwaukee, Wisconsin, 53226, United States
H Lee Moffitt Cancer Center & Research Institute
RECRUITING

Tampa, Florida, 33612, United States
Imperial College Healthcare NHS Trust, Hammersmith Hospital
RECRUITING

London, W12 0HS, United Kingdom
John Theurer Cancer Center at Hackensack University Medical Center
RECRUITING

Hackensack, New Jersey, 07601, United States
King's College Hospital NHS Foundation Trust
RECRUITING

London, SE5 9RS, United Kingdom
Levine Cancer Institute
RECRUITING

Charlotte, North Carolina, 28204, United States
Mayo Clinic
RECRUITING

Rochester, Minnesota, 55905, United States
Mayo Clinic Arizona
RECRUITING

Phoenix, Arizona, 85054, United States
Mayo Clinic Florida
RECRUITING

Jacksonville, Florida, 32224, United States
Oxford University Hospitals NHS Foundation Trust
RECRUITING

Oxford, OX3 7LE, United Kingdom
Royal Marsden NHS Foundation Trust
RECRUITING

Sutton, London, SM2 5PT, United Kingdom
Rutgers Cancer Institute of New Jersey
RECRUITING

New Brunswick, New Jersey, 08901, United States
The Christie NHS Foundation Trust
RECRUITING

Withington, Greater Manchester, M20 4BX, United Kingdom
The Clatterbridge Cancer Centre NHS Foundation Trust
RECRUITING

Bebington, Wirral, CH63 4JY, United Kingdom
University Hospital Southampton NHS Trust, Southampton General Hospital
RECRUITING

Southampton, SO16 6YD, United Kingdom
University Hospital of Wales
RECRUITING

Cardiff, Wales, CF14 4XW, United Kingdom
University of California, San Francisco
RECRUITING

San Francisco, California, 94143, United States
University of Chicago Medical Center
RECRUITING

Chicago, Illinois, 60637, United States
University of Michigan
RECRUITING

Ann Arbor, Michigan, 48109, United States
University of Nebraska Medical Center
RECRUITING

Omaha, Nebraska, 68198, United States
University of Pennsylvania, Abramson Cancer Center
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
Wake Forest University Health Sciences
RECRUITING

Winston-Salem, North Carolina, 27157, United States
Washington University School of Medicine
RECRUITING

St Louis, Missouri, 63110, United States
Western General Hospital
RECRUITING

Edinburgh, EH4 2XU, United Kingdom
Winship Cancer Institute
RECRUITING

Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.